Back to Search
Start Over
Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts.
- Source :
-
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2017 Apr; Vol. 361 (1), pp. 140-150. Date of Electronic Publication: 2017 Feb 07. - Publication Year :
- 2017
-
Abstract
- Inhibitors of zinc-dependent histone deacetylases (HDACs) profoundly affect cellular function by altering gene expression via changes in nucleosomal histone tail acetylation. Historically, investigators have employed pan-HDAC inhibitors, such as the hydroxamate trichostatin A (TSA), which simultaneously targets members of each of the three zinc-dependent HDAC classes (classes I, II, and IV). More recently, class- and isoform-selective HDAC inhibitors have been developed, providing invaluable chemical biology probes for dissecting the roles of distinct HDACs in the control of various physiologic and pathophysiological processes. For example, the benzamide class I HDAC-selective inhibitor, MGCD0103 [ N -(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl] benzamide], was shown to block cardiac fibrosis, a process involving excess extracellular matrix deposition, which often results in heart dysfunction. Here, we compare the mechanisms of action of structurally distinct HDAC inhibitors in isolated primary cardiac fibroblasts, which are the major extracellular matrix-producing cells of the heart. TSA, MGCD0103, and the cyclic peptide class I HDAC inhibitor, apicidin, exhibited a common ability to enhance histone acetylation, and all potently blocked cardiac fibroblast cell cycle progression. In contrast, MGCD0103, but not TSA or apicidin, paradoxically increased expression of a subset of fibrosis-associated genes. Using the cellular thermal shift assay, we provide evidence that the divergent effects of HDAC inhibitors on cardiac fibroblast gene expression relate to differential engagement of HDAC1- and HDAC2-containing complexes. These findings illustrate the importance of employing multiple compounds when pharmacologically assessing HDAC function in a cellular context and during HDAC inhibitor drug development.<br /> (Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.)
- Subjects :
- Animals
Animals, Newborn
Cells, Cultured
Histone Deacetylase 1 antagonists & inhibitors
Histone Deacetylase 1 metabolism
Histone Deacetylase Inhibitors metabolism
Mice
Mice, Inbred C57BL
Rats
Rats, Sprague-Dawley
Fibroblasts drug effects
Fibroblasts enzymology
Histone Deacetylase Inhibitors chemistry
Histone Deacetylase Inhibitors pharmacology
Myocytes, Cardiac drug effects
Myocytes, Cardiac enzymology
Subjects
Details
- Language :
- English
- ISSN :
- 1521-0103
- Volume :
- 361
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- The Journal of pharmacology and experimental therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 28174211
- Full Text :
- https://doi.org/10.1124/jpet.116.237701